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Abstract  
 
Background Systemic sclerosis (SSc) is a chronic autoimmune disease characterised by 
tissue fibrosis and immune abnormalities. Recent evidence suggests that activated circulating 
monocytes from SSc patients play an important role in early stages of SSc pathogenesis due 
to enhanced expression of tissue inhibitor of metalloproteinases 1 (TIMP-1), IL-8 and 
reactive oxygen species (ROS) induction. However, the exact factors that contribute to 
chronic inflammation and subsequently fibrosis progression are still unknown.  
Material and methods The expression pattern of IL-8, TIMP-1, AP-1 transcription factor-
Fra2 and ROS induction in peripheral blood monocytes following DZNep (histone 
methyltransferase inhibitor) and TLR8 agonist stimulation was investigated. Exogenous 
microRNA-5196, which is predicted to bind ¶875RIFra-2 gene, was delivered in order to 
reverse profibrotic phenotype in monocytes. Expression of circulating microRNA-5196 was 
correlated with SSc parameters.  
Results DZNep+TLR8 agonist stimulation enhanced profibrotic TIMP-1, IL-8 and ROS 
generation in HC and SSc monocytes. As opposed by the decrease of miRNA-5196 and 
antioxidant SOD1 expression in SSc monocytes. Exogenous delivery of microRNA-5196 
reduced Fra2 and TIMP-1 expression suggesting that it may be used as a potential modulator 
of fibrogenesis in SSc. Circulating microRNA-5196 was significantly increased in SSc and 
positively correlated with CRP level but not with Rodnan skin score or ESR. 
Conclusions These results suggest that microRNA-5196 can be used as a potential biomarker 
characterising SSc. Overall, this study may open new possibilities for the development of 
microRNA-5196-based diagnostics and therapy in early phases of SSc.  
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Introduction 
Systemic sclerosis (SSc) is a chronic multisystem autoimmune disease characterised by skin 
and internal organs fibrosis and immune abnormalities. Recent evidence suggests that 
activated circulating monocytes from SSc patients play an important role in SSc pathogenesis 
due to enhanced expression of tissue inhibitor of metalloproteinases 1 (TIMP-1) which likely 
contributes to accumulation of extracellular matrix protein (ECM) [1]. Also, the level of 
TIMP-1 is elevated in SSc sera and in affected skin tissue, as opposed to reduced level of 
matrix proteinases (MMPs) which directly contribute to fibrosis development [2, 3].  
Another factor promoting SSc progression during early phases of disease is inflammation 
initiated by the Toll-like receptors (TLRs) signaling pathway. It has been reported that TLR 
stimulated monocytes are involved in SSc development through increased production of 
proinflammatory cytokines such as IL-6, TNF-Į or by driving profibrotic phenotype [4-6]. 
Furthermore, reactive oxygen species (ROS) has been suggested to contribute to scleroderma 
pathogenesis. In particular, it has been shown that skin fibroblasts from SSc patients release 
more ROS compared to normal fibroblasts. This consequently induces enhanced proliferation 
and production of collagen in SSc fibroblasts [7]. Similarly, blood phagocytes from SSc 
patients, especially from those with interstitial lung disease, release more ROS than 
phagocytes from healthy individuals [8]. Also, scleroderma-associated autoantigens, that are 
involved in breaking the tolerance, are specifically susceptible to ROS-mediated 
fragmentation and processing, which supports an important role of ROS production in SSc 
pathogenesis [9]. The effect of ROS induction is mostly limited by antioxidant enzyme 
superoxide dismutase 1 (SOD1) in order to restore cellular redox homeostasis [10]. 
Moreover, AP-1 transcription factor family which is composed of proteins including Fos-
related antigen 2 (Fra2) play an important role in SSc development. Indeed, Fra2-transgenic 
mice are a widely used mouse model of SSc mimicking systemic manifestations [11]. Also, 
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in bleomycin-treated mice and in skin biopsies from SSc patients the level of Fra2 is 
increased [12]. It has been demonstrated that Fra2 regulates the production of matrix protein, 
including collagen, both in patients and animal models for SSc [13]. Our recent studies have 
also shown that stimulation with TLR8 ligand enhanced Fra2 and its target gene TIMP-1 
expression in SSc monocytes compared to healthy controls. Furthermore, increased 
production of TIMP-1 in monocytes leads to trans-differentiation of fibroblast towards 
pathogenic myofibroblasts phenotype suggesting that monocytes have impact on the 
pathogenesis of SSc [12]. However, precise mechanisms involved in the contribution of 
monocytes in inflammation and fibrotic progression remain largely unknown. 
A growing body of evidence suggests that epigenetic mechanisms, including microRNAs 
(miRNAs), mediate in SSc development. MiRNAs are small noncoding RNA molecules that 
negatively regulate gene expression via degradation or translational repression of their 
targeted mRNA transcripts. It is known that expression of miRNAs can be altered under 
conditions of pathophysiological stress or disease, allowing miRNAs to be important 
biomarkers and attractive candidates for therapeutic manipulation. Indeed, our recent studies 
have shown reduced level of miRNA-135b in sera, monocytes and fibroblasts from SSc 
patients [14]. In addition, IL-13-mediated collagen induction was inhibited in fibroblasts 
transfected with miRNA-135b targeting STAT6. 
 
 
The aim of this study was to investigate the expression pattern of AP-1 transcription factor - 
Fra2, TIMP-1, IL-8 and ROS induction in peripheral blood monocytes from HC and SSc 
patients following DZNep (histone methyltransferase inhibitor) and TLR8 agonist (ssRNA) 
stimulation. In addition, the effect of miRNA-5196 targeting Fra2 was evaluated in order to 
reverse fibrotic properties of monocytes. The level of circulating miRNA-5196 was measured 
This article is protected by copyright. All rights reserved. 
in sera from SSc patients for diagnostic purposes. Thus, identification whether miRNA-5196 
can both modulate profibrotic genes and be used as a biomarker may open up new therapeutic 
approaches and diagnostic tools in SSc. 
 
Materials and methods 
Sample collection and cell purification 
Twenty two patients who fulfilled the American College of Rheumatology criteria according 
to LeRoy for the classification of SSc [15] were obtained from Wroclaw Medical University. 
This study was approved by the local ethics committee (approval no. 335/2014) SSc patients 
provided fully informed written consent. Their clinical characteristics and treatment are 
summarised in Table 1 and 2, respectively. Twenty one donors with no history of 
autoimmune disease were included as healthy control. The blood from healthy controls (HC) 
was collected from a local blood donor centre or directly from healthy volunteers. The blood 
was collected in EDTA-coated tubes from HC and SSc patients. Peripheral blood 
mononuclear cells (PBMC) were separated from whole red blood cells as described 
elsewhere [1]. To isolate monocytes fraction, PBMC were incubated with anti-CD14+ beads 
(Miltenyi-Biotec) according to the manufactureU¶V protocol. Serum samples from HC, RA 
and SSc patients were collected in serum separation tubes (BD Vacutainer® SST II Plus), 
aliquoted and frozen at -20°C.  
Compounds, reagents and in vitro cell cultures  
Monocytes from HC, SS patients and U937 monocytic cell line were seeded in 24-well plates 
at the concentration of 0.5-1×106 cells/ml and cultured for 24 h in 500 µl of RPMI 
(Laboratory of General Chemistry, IITD Poland) supplemented with penicillin (100 U/ml), 
streptomycin (100 µg/ml), L-glutamine (2 mM) and 10% FBS (all from Life Technologies) at 
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37°C in 5% CO2. Cells were stimulated for 24 h with 2 ȝg/ml TLR8 agonist 
(ssRNA40/LyoVec, InvivoGen) and 20 µM DZNep (4703, Tocris) or 100 ng/ml apicidin 
(A8851, Sigma).  
Gene expression study 
RNA from freshly isolated HC or SSc monocytes or U937 monocytic cell line was obtained 
using the RNA mini kit (Genoplast), according to the manufacturer's protocol. RNA (200±
500 ng) was reverse transcribed to cDNA with the use of random primers and reverse 
transcriptase enzyme (Life Technologies) according to the manufacturer's protocol. Samples 
(20 ng of cDNA) were analysed in triplicate using the Viia 7 qRT-PCR machine (Thermo 
Fisher Scientific). Expression levels relative to the average healthy control (arbitrarily set at 
1) were calculated usLQJWKHIROORZLQJHTXDWLRQA'HOWD'HOWD&7íDOOQRUPDOLVHGWR6
housekeeping gene (Table 3).  
ELISA and nuclear fraction isolation for Fra2 activity assay measurement  
TIMP-1 protein concentrations in culture supernatants were measured by ELISA, according 
to the manufacturer's protocol (Human TIMP-1 DuoSet, DY970, R&D Systems). To identify 
Fra2 transcription factor activities, Fra2-TFactTM DNA binding ELISA Kit (TFE-7014 
antibodies) was used according to the manufacturer's protocol. Nuclear fraction was isolated 
using centrifugation at 3000 x g DWÛ& for 30 min according to the manufacturer's protocol. 
Oxidative stress measurement  
To determine oxidative stress induction in monocytes, bioluminescent ROS-GloTM H2O2 
Assay (Promega) was used according to the manufacturer's protocol. Luminescence was 
measured using detection system GloMax® 96 Microplate Luminometer (Promega).  
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MiRNA experiments and computational analysis 
Computational prediction analysis of miRNA-5196 targeting Fra2 was performed using 
computational prediction algorithms. Pre-miRNA-5196 (Thermo scientific, UK) was 
transfected into 8PRQRF\WLFFHOOOLQHDW(?Q0FRQFHQWUDWLRQXVLQJViromer transfection 
reagent (Lipocalyx GmbH) in antibiotic and FBS-free medium along with the control miRNA 
(?Q0 IRU  KThe sequence of the control non-targeting miRNA was designed to be 
complementary to the nematode worm C. elegans. The volume of 300 µl of serum was used 
to isolate circulating miRNA-5196 using NucleoSpin® miRNA plasma/serum (Macherey-
Nagel) according to the manufacturer's protocol. TaqMan ® microRNA RT Kit (Thermo 
Fisher Scientific) was used to reverse transcribe to cDNA with the use of TaqMan® 
MicroRNA Assays for hsa-miR-5196-5q (471527_mat), and hsa-let-7a (000377) all from 
Thermo Fisher Scientific was used as a stabile control.  
Statistical analysis 
All data are presented as mean±SEM. The differences between the groups were tested for 
their statistical significance by non-parametric two tailed T-test using GraphPad Prism 
(GraphPad Software). A p value of less than 0.05 was considered statistically significant; p 
values are expressed as follows: ns for not significant; 0.05>p>0.01 as*; 0.01>p>0.001 as**; 
p<0.001 as***.  
 
Results 
Enhanced TIMP-1 secretion and reduced expression of MMPs in SSc monocytes  
We have previously demonstrated that HC monocytes increased expression of Fra2 and 
TIMP-1 following DZNep+TLR8 treatment [12], therefore we wanted to measure Fra2 and 
TIMP-1 levels in patients monocytes and to test if stimulation even further enhances 
profibrotic genes in SSc monocytes. In order to do that, HC and SSc monocytes were 
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stimulated as previously with TLR8 ligand (ssRNA) and DZNep for 24 h. It can be seen that 
the level of Fra2 was increased in the presence of DZNep+TLR8 in both HC (p=0.001, 2.1-
fold) and SSc (p=0.024, 1.9-fold) monocytes, however there was no difference between HC 
and SSc monocytes population (Fig. 1a). In contrast, secreted level of TIMP-1 was elevated 
in both unstimulated and stimulated SSc monocytes and was significantly higher (p=0.016, 
2.1-fold) in SSc than in HC monocytes (Fig. 1b).  
Furthermore, we also looked on Fra2-transcriptional activity upon DZNep+TLR8 
stimulation. It is well known that Fra2 regulates TIMP-1 expression and plays an important 
role in SSc pathogenesis [13, 16]. In order to test that, we used the colorimetric DNA-binding 
assay in which we measured only the translocated Fra2 into the nucleus of U937 monocytic 
cell line. Although the Fra2 DNA-binding activity did not reach statistical significance 
(p=0.412) upon stimulation, the tendency mirrored upregulated Fra2 gene expression as seen 
in primary monocytes (Fig. 1c).  
We also examined the morphology of DZNep+TLR8 treated monocytes. It can be seen in 
Fig. 1d that DZNep+TLR8 treatment led to cell elongation and aggregation as compared to 
monocytes treated with DZNep, apicidin, TLR8 alone or aicidin plus TLR8 agonist. Apicidin 
is another histone modifier inducing histones hyperacetylation. We have previously validated 
that DZNep and apicidin concentrations, which were used to stimulate monocytes, did not 
affect cells viability [12]. This suggests that only specific epigenetic agent (DZNep, but not 
apicidin) plus TLR8 stimulation can activate monocytes to produce profibrotic genes and 
changes cell morphology. We have also measured the expression levels of MMP-1 and 
MMP-15 following stimulation. The balance between TIMP-1 and MMPs is altered in SSc 
leading to abnormal ECM formation, thus we wanted to test if profibrotic stimulation can 
result in even further TIMP-1/MMPs balance disruption. It can be seen that the basal gene 
expression levels of MMP-1 (Fig. 1e) and MMP-15 (Fig. 1f) were significantly decreased 
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(p=0.034, 2.4-fold, p=0.018, 2.6-fold, respectively) in SSc monocytes. However, 
DZNep+TLR8 stimulation did not affect MMPs expression. Although MMP1 and MMP-15 
promoters have similar AP-1 binding sites as TIMP-1 [17], these data suggest that stimulation 
with DZNep+TLR8 specifically induces only profibrotic TIMP-1 but not MMPs expression. 
 
DZNep+TLR8-dependent induction of IL-8 and oxidative stress in HC and SSc 
monocytes  
It is well known that inflammation during early phases of disease play an important role in 
fibrogenesis and subsequent SSc progression. Therefore, we tested if DZNep+TLR8 can also 
induce production of proinflammatory mediators in monocytes. As previously, HC and SSc 
monocytes were stimulated with DZNep+TLR8 agonist for 24 h and the expression of IL-8 
and ROS was measured.  
It can be seen in Fig. 2a that the expression of IL-8 was strongly elevated following 
stimulation in both HC and SSc monocytes (p=0.003, 4.6-fold and p=0.0008, 7.8-fold, 
respectively). Similarly, DZNep+TLR8-induced ROS secretion was significantly increased 
(p=0.039, 2.3-fold) compared to untreated HC monocytes (Fig. 2b). Due to the limitation of 
SSc patients¶ PDWHULDO, we tested the DZNep+TLR8-mediated ROS induction only in HC 
monocytes. In order to measure ROS release, we used ROS-Glo H2O2 assay. This 
bioluminescent assay measures generated ROS directly in cell cultures.  
To better understand changes in redox balance induced by DZNep+TLR8, we also analysed 
the SOD1 gene expression. SOD1 is a major anti-oxidative enzyme. As expected, the level of 
SOD1 was significantly (p=0.025, 2.4-fold) decreased in HC monocytes (Fig. 2c). Although 
the SOD1 expression was significantly attenuated in HC monocytes only, the tendency of 
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reduced (1.77-fold) SOD1 expression was also seen in SSc monocytes, implying that redox 
homeostasis is disturbed upon the DZNep+TLR8 treatment. 
 
Exogenous transfection of miRNA-5196 reduced profibrotic properties in 
DZNep+TLR8-treated monocytes  
We then used a computational algorithm to identify possible miRNAs that target the 
downstream signal molecule Fra2. Based on bioinformatics analysis, we have selected 
miRNA-5196 because it hybridises WR  VHHG UHJLRQV RI ¶87R of Fra2 transcript in the 
position of 45-51, 361-367, 404-410, 592-458, 1055-1061 (Fig. 3a). Formation of such 
duplexes lead to miRNA-mediated transcriptional repression. Subsequently, to evaluate the 
functional effect of miRNA-5196 repression on profibrotic genes, HC monocytes were 
transfected with exogenous miRNA-5196 following DZNep+TLR8 stimulation and both Fra2 
and TIMP-1 expression levels were measured. As shown in Fig. 3b, the expression level of 
Fra2 was significantly reduced (p=0.0001, 4.1-fold) upon miRNA-5196 transfection in 
stimulated monocytes. In contrast, the Fra2 expression was only slightly reduced in 
monocytes transfected with non-targeting miRNA (scramble miRNA), suggesting specific 
binding of miRNA-5196 to Fra2 target gene (Fig. 3b). Accordingly, TIMP-1 was 
significantly attenuated (p=0.046, 2.1-fold) in miRNA-5196 transfected monocytes, but not 
in scramble treated monocytes. These findings imply that miRNA-5196 negatively regulates 
its target gene Fra2 and indirectly TIMP-1 following stimulation.  
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Elevated level of miRNA-5196 in monocytes and sera from SSc patients  
Since Fra2 plays an important role in SSc pathogenesis, we have analysed whether the 
expression of miRNA-5195 targeting Fra2 is abrogated in monocytes and sera from SSc 
patients. As shown in Fig. 4a, miRNA-5196 was significantly (p=0.014) elevated in SSc 
monocytes compared to HC, however treatment with DZNep+TLR8 resulted in further 
reduction of miRNA-5196 expression in SSc monocytes (p=0.003, 1.8-fold). This implies 
that the DZNep+TLR8 treatment not only induces profibrotic (Fra2, TIMP-1) and 
proinflammatory mediators (IL-8 and ROS), but it also reduces antifibrotic miRNA5196. 
Next, we measured the expression level of circulating miRNA-5196 in sera in order to 
determine whether miRNA-5196 can be used as a potential biomarker for SSc. The level of 
miRNA-5196 was significantly elevated in all SSc patients (p=0.001, 3-fold) (Fig. 4b). 
Interestingly, the patients with limited SSc (lSSc) had 2.7-times higher level of miRNA-5196 
compared to patients with diffused SSc and 3.79-fold increased level of miRNA-5196 
(p=0.0001) compared to HC sera. In addition, there was a positive correlation (p=0.03) based 
on Spearman analysis between the miRNA-5196 expression and the CRP level in SSc sera 
(Fig. 4c). However, no correlation was seen between miRNA-5196 and Rodnan skin score 
(Fig. 4d) and between miRNA-5196 and ESR (Figure 4e), probably due to a limited number 
of samples. CRP is a general inflammatory parameter, suggesting that miRNA-5196 can help 
to monitor disease severity and to understand its pathogenesis. Indeed, it has been shown that 
the increased level of CRP correlates with disease activity, severity, poor pulmonary function 
and shorter survival of SSc patients [18]. Therefore, miRNA-5196 along with CRP, but not 
with ESR, level may be used for better SSc diagnosis and to provide information of the 
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disease outcome. We also measured the expression level of circulating miRNA-5196 in sera 
of other rheumatic disease including RA. The level of miRNA-5196 was significantly 
elevated (data not shown), suggesting that miRNA-5196 can be used as a potential biomarker 
for other rheumatic disease including RA. 
Discussion 
Systemic sclerosis (SSc) is a complex autoimmune connective tissue disease characterised by 
vascular injury, inflammation and tissue fibrosis. Inflammation in SSc is mediated mostly by 
the tissue infiltrating CD14+ monocytes where they can differentiate into macrophages or 
dendritic cells during early phases of the disease [19]. SSc monocytes also display the 
elevated level of collagen and Į-SMA, which indicates their maturation towards 
myofibroblasts and their important role in fibrogenesis [20].  
To date, much evidence underscores the effect of environmental factors, including viral 
infection activating the TLR signaling pathway, smoking or pollution on SSc pathogenesis 
[21-23]. It has been reported that environmental factors are associated with epigenetic 
abnormalities contributing to inflammation and fibrosis development in SSc [23-25]. This 
suggests that abnormal SSc monocytes, responsible for initiation of inflammation and 
subsequently fibrosis, may develop from a subset of cells that have escaped from a normal 
control mechanisms following exposure to environmental agents. Furthermore, there is a 
strong correlation between inflammation and fibrosis by upregulation of proinflammatory and 
profibrotic markers in SSc sera and in affected skin tissue [26, 27]. Thus, finding the 
mechanisms which will modulate inflammation and fibrosis mediated by circulating 
monocytes may provide therapeutic opportunities to treat SSc in early stages of disease.  
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Our findings demonstrate that epigenetic modification induced by the histone methylation 
inhibitor (DZNep) and the activation of TLR8 signaling pathway lead to the increased 
expression TIMP-1 and its upstream mediator Fra2 both in HC and SSc monocytes (Fig. 1). 
The increased profibrotic gene expression was compatible with morphological changes in 
activated monocytes. Fig. 1d illustrates that only DZNep+TLR8 stimulated monocytes had 
elongated shapes and form spheres, but not in DZNep or TLR8 alone or in apiciding+TLR8 
treated cells. Apicidin is another epigenetic modifier inducing histone hyperacetylation by 
inhibition of histone deacetylase. This is consistent with our previous results showing the 
synergistic effect of DZNep+TLR8 stimulation on TIMP-1 expression and the induction of 
fibroblasts transdifferentiating by HC monocytes, but not in apicidin+TLR8 treated cells [1]. 
These data imply that only a specific epigenetic modification along with TLR8-activation is 
able to induce profibrotic properties in monocytes.  
Since the balance between TIMPs/MMPs is altered in SSc leading to abnormal ECM 
formation, we have also measured the expression levels of MMP-1 and MMP-15, which 
catalytic activity is blocked by TIMPs. We have noted that the basal levels of MMP-1 and 
MMP-15 were significantly reduced (p=0.034, p=0.018, respectively) in SSc monocytes 
compared to HC. Further stimulation did not affect MMPs expression (Fig. 1h, i) suggesting 
that DZNep+TLR8 treatment changes TIMP-1/MMPs ratio only by enhanced TIMP-1 
production.  
Next, we have shown the induction of proinflammatory mediators including IL-8 and ROS 
and the reduced expression of antioxidant enzyme SOD1 in HC and SSc monocytes, 
suggesting the disturb redox homeostasis upon treatment (Fig. 2). Indeed, it has been 
demonstrated that ROS promotes a profibrotic phenotype in SSc fibroblasts by inducting the 
collagen and autoantigens development [9, 28]. Another study has reported that direct 
injection of ROS induces local formation of DNA-topoisomerase autoantibodies and 
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development of lung and skin fibrosis in mouse model [29]. Similarly, the increased level of 
IL-8 in SSc sera correlates with the severity of a disease [30, 31]. This suggests that 
proinflammatory IL-8 and ROS play an important role in SSc pathogenesis.  
In order to reduce DZNep+TLR8-mediated profibrotic phenotype of monocytes, we used the 
miRNA specifically targeting Fra2 transcription factor and subsequently TIMP-1 expression 
(Fig. 3). Based on prediction algorithms we selected miRNA-5196 which binds to 5 seed 
regions withLQ¶875of Fra2. Next, we tested if a computational analysis can be applicable 
in experimental approaches. Indeed, the exogenous transfection of miRNA-5196 significantly 
reduced the expression of Fra2 and TIMP-1. In contrast, transfection with non-targeting 
miRNA derived from C. elegance did not reduce expression of Fra2 and TIMP-1 following 
DZNep+TLR8 stimulation. This suggests that only a VSHFLILFELQGLQJZLWKLQ¶875UHVXOWHG
in direct Fra2 reduction and indirect TIMP-1 inhibition. Similarly, we have previously found 
that exogenous transfection with miRNA-29a targeting TAB1 reversed profibrotic phenotype 
of SSc fibroblasts by indirect inhibition of TIMP-1 [32]. TAB1 is the TGF-ȕ-dependent 
upstream mediator regulating TIMP-1. Another study also showed therapeutic role of miRNA 
in SSc fibroblasts. Transfection with miRNA-29 targeting collagen reversed profibrotic 
phenotype of SSc fibroblast, which implies that specific miRNAs targeting profibrotic genes 
could be used in SSc therapy. [33]. Next, we compared the level of miRNA-5196 between 
HC and SSc monocytes (Fig. 4). The basal level of miR-5196 was elevated in SSc monocytes 
compared to HC, however stimulation with DZNep+TLR8 significantly reduced miRNA-
5196 expression in SSc monocytes. This demonstrates that DZNep+TLR8 stimulation not 
only induces the secretion of TIMP-1 and ROS but also reduces the expression of antifibrotic 
miRNA-5196 and antioxidant SOD1, which subsequently develops pathogenic properties of 
monocytes. 
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Although miRNAs are already tested in gene therapies, numerous studies have also explored 
that miRNA could be used as a potential biomarker due to their specificity, stability and 
release under conditions of pathophysiological stress or disease. Moreover, miRNA can be 
easily available from circulatory biofluids eliminating painful biopsies. Some miRNAs have 
been already validated as versatile biomarkers of rheumatic diseases. In particularly, 
abnormal expression of miRNA-146a has been described in several rheumatic diseases 
including RA, Systemic lupus erythematosus or 6M|JUHQ¶V V\QGURPH [34-36]. Thus, finding 
circulating biomarkers reflecting ongoing inflammatory or fibrotic processes may provide a 
promising new direction for future diagnosis of SSc and probably other rheumatic diseases. 
We have shown that circulating miRNA-5196 was significantly elevated in SSc sera and 
monocytes compared to healthy controls (Fig. 4). This suggests that increased level of 
miRNA-5196 may serve as a compensatory mechanism to restore proper expression its 
indirect target gene TIMP-1 which is regulated by Fra2. Also, upregulated serum expression 
of miRNA-5196 positively correlated with the CRP level in SSc patients. These findings 
indicate that miRNA-5196 can be used as a biomarker of inflammation suggesting of SSc 
activity and severity. Our data are similar to other findings showing that miRNA-29c was 
readily detected from urinary exosomes and correlated with progression of renal fibrosis in 
patients with lupus nephritis [37]. Also, circulating miRNA-223 positively correlated with 
CRP and DAS28 score in patients with early RA [38].  
 
 
In conclusion, we have shown for the first time that the epigenetic agent (DZNep) and TLR8 
agonist mimicking viral infections upregulate TIMP-1 and inflammatory markers including 
ROS and IL-8 in HC and SSc monocytes. Fra2-mediated TIMP-1 production was blocked by 
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miRNA-5196 in profibrotic monocytes. Furthermore, the increased expression of miRNA-
5196 in SSc sera positively correlated with the CRP level, but not with ESR. Overall, our 
study may open new possibilities for the development of miRNA-5196-based diagnostics and 
therapy for SSc.  
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Figure legends 
 
 
 
Figure 1. The effect of DZNep+TLR8 stimulation on profibrotic properties induction in 
monocytes. HC and SSc monocytes were treated for 24 h with TLR8 lignad+DZNep and 
expression of Fra2 (a) and TIMP-1 synthesis (b) were measured. Nuclear fraction (n=5) was 
isolated from 24 h DZNep+TLR8 treated or untreated U937 monocytic cell line (c). 
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Morphological changes in HC monocytes following treatment were observed using light 
microscope (d). White arrows indicate cells aggregation and black arrow indicates elongated 
shape. Magnification used 20x. HC and SSc monocytes were DZNep+TLR8 treated for 24 h 
and MMP-1 (e) or MMP-15 (f) expression were measured. 
 
 
 
 
 
Figure 2. DZNep+TLR8-mediated IL-8, ROS, SOD1 expression. HC and SSc monocytes 
were DZNep+TLR8 treated for 24 h and IL-8 (a) and SOD1 (c) expression were measured. 
ROS induction was measured in HC monocytes (n=9) (b). 
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Figure 3. MiRNA-5196 reverses profibrotic phenotype in monocytes. Based on prediction 
algorithms, miRNA-5196 binds into 5 regions of ¶875RI)UD LQSRVLWLRQV49, 361, 404, 
592, 1055 (a). HC monocytes were transfected with exogenous miRNA-5196 or scramble 
miRNA prior to DZNep+TLR8 stimulation and Fra2 (b) and TIMP-1 (c) were measured.  
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Figure 4. Increased level of miRNA-5196 in monocytes and sera from SSc patients. HC 
(n=9) and SSc (n=10) monocytes were DZNep+TLR8 treated for 24 h and miRNA-5196 was 
measured (a). Circulating miRNA-5196 was measured in HC (n=21), SSc sera (n=16) 
including lSSc (n=11) and dSSc (n=5) (b) and correlated with CRP level (c), Rodnan skin 
score (d) and ESR (e). 
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Table 1. Clinical and laboratory data of SSc patients.  
 
Parameters of SSc SDWLHQWVQ(? (?) SSc Patients 
Age, years, median (range) 65 (27±86) 
Sex F/M 18/4 
Disease duration, years, average (range) 4 (0±12) 
diffuse SSc, % (n) 36 Q(? (?8) 
limited SSc, % (n) 64 Q(? (?4) 
5D\QDXG¶VSKHQRPHQRQn) Q(? (?) 
modified Rodman skin score in 17 body surfaces 0-3, median, 
(range)  
13 (6-29) 
pulmonary hypertension, % (n) Q(? (?) 
lung fibrosis, % (n) 41 % (n=9) 
Smoker, % (n) 32 % (n=7) 
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Parameters of SSc SDWLHQWVQ(? (?) SSc Patients 
CRP, mg/L, median (range) 4.64 (1.12±34.49) 
ESR, mm/h (range)  17.94 (6-49) 
Active SSc  24% (n=5) 
ACA, % (n) 22 % (n=5) 
ANA, % (n) 95 % (n=21) 
SCL-70, % (n) 50 % (n=11) 
Anti-RNP, % (n) 9 % (n=2) 
 
 
Table 2. Treatment of SSc patients.  
 
 
 
 
  
Treatment 
 
Prednisone, % (dose of treated patients) 9 % (5 mg) 
Methylprednisolone, % (dose of treated patients) 13 % (2-4 mg) 
Azathioprine, % (n) 18 % (n=4) 
Cyclophosphamide, % (n) Q(? ) 
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Table 3. Sequence of primers and numbers of probes used in gene expression study. 
 
Gene Forward primer Reverse primer TaqMan Gene Expression 
Assays (Thermo Fisher 
Scientific) 
Fra2 5'-ACG CCG AGT 
CCT CTC CA-ƍ 
5'-TGA GCC AGG CAT 
ATC TAC CC-ƍ 
 
TIMP-1 ƍ-GAC GGC CTTC 
TGC AAT TCC-ƍ 
ƍ-GTG GTC TGG TTG 
ACT TCT G-ƍ 
 
18S 5'-GAA TGG CTC 
ATT 
AAATCAGTTATGG-
3' 
5'-TAT TAG CTC TAG 
AAT 
TACCACAGTTATCC-3' 
 
MMP-1 5'-AGT GAC TGG 
GAA ACC 
AGATGCTGA-3' 
5'-GCT CTT GGC 
AAATCTGGCCTGTAA-¶ 
 
SOD1   Hs00916176_m1, Amplicon 
Length 138 
IL-8   Hs00174103_m1, Amplicon 
Length 101 
MMP-15   Hs00233997_m1, Amplicon 
Length 68 
18S   Hs99999901_s1, Amplicon 
Length 187 
 
